Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Profit After Tax: 2020-2024

Historic Profit After Tax for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$34.1 million.

  • SAB Biotherapeutics' Profit After Tax rose 539.11% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.7 million, marking a year-over-year increase of 141.13%. This contributed to the annual value of -$34.1 million for FY2024, which is 19.17% up from last year.
  • As of FY2024, SAB Biotherapeutics' Profit After Tax stood at -$34.1 million, which was up 19.17% from -$42.2 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Profit After Tax registered a high of $20.1 million during FY2020, and its lowest value of -$42.2 million during FY2023.
  • Over the past 3 years, SAB Biotherapeutics' median Profit After Tax value was -$34.1 million (recorded in 2024), while the average stood at -$31.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 185.22% in 2021, then grew by 19.17% in 2024.
  • SAB Biotherapeutics' Profit After Tax (Yearly) stood at $20.1 million in 2020, then plummeted by 185.22% to -$17.1 million in 2021, then declined by 9.31% to -$18.7 million in 2022, then tumbled by 125.14% to -$42.2 million in 2023, then grew by 19.17% to -$34.1 million in 2024.